Chronic constrictive pericarditis induced by long-term bromocriptine therapy:: Report of two cases

被引:9
作者
Champagne, SP
Coste, E
Peyrière, H
Nigond, J
Mania, E
Pons, M
Hillaire-Buys, D [1 ]
Balmes, P
Blayac, JP
Davy, JM
机构
[1] CHU Montpellier, St Charles Hosp, Ctr Pharmacovigilance, F-34295 Montpellier 5, France
[2] Arnaud de Villeneuve Hosp, Dept Cardiol, Montpellier, France
[3] Gaston Doumergue Hosp, Dept Pneumol, Nimes, France
[4] Hosp E Borel, Dept Med, St Afrique, France
关键词
Parkinson's disease; bromocriptine; constrictive pericarditis;
D O I
10.1345/aph.18461
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To report two cases of chronic constrictive pericarditis that appear to be related to the intake of bromocriptine for Parkinson's disease. CASE SUMMARY: TWO white men (aged 63 and 69 y) were treated with bromocriptine for four (40 mg/d) and two years (30 mg/d), respectively, with a cumulative dose intake of 58.4 and 21.9 g, respectively. The patients experienced dyspnea with bilateral lower-limb edema and pleural effusion, suggesting right cardiac dysfunction. Echocardiography, computed tomography, and cardiac catheterization results were compatible with a diagnosis of constrictive pericarditis, so pericardectomy was performed on both patients. The anatomic pathology examination showed a fibrous pericardium; cultures were sterile. In the first case, pleural effusion recurred seven months after the pericarditis; bromocriptine was suspected and treatment was discontinued. In the second case, just prior to the pericardectomy, an episode of mental confusion occurred and prompted the cessation of bromocriptine therapy. DISCUSSION: To the best of our knowledge, only one case of constrictive pericarditis induced by bromocriptine therapy has previously been described in the literature. CONCLUSIONS: Our eases call attention to a possible association between bromocriptine use in patients who have Parkinson's disease and constrictive pericarditis.
引用
收藏
页码:1050 / 1054
页数:5
相关论文
共 20 条
[1]  
Benard A, 1996, REV MAL RESPIR, V13, P227
[2]   Clozapine induced polyserositis [J].
Catalano, G ;
Catalano, MC ;
Wetter, RLF .
CLINICAL NEUROPHARMACOLOGY, 1997, 20 (04) :352-356
[3]  
DARMON M, 1997, REV MED INTERNE S2, V18, pS165
[4]  
DIOT E, 1990, REV MAL RESPIR, V7, P175
[5]   AN UNUSUAL SIDE-EFFECT OF LONG-TERM METHYSERGIDE TREATMENT [J].
HODGSON, RS ;
HERKES, GK ;
MARSHMAN, D .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1995, 25 (02) :171-171
[6]   RETROPERITONEAL FIBROSIS IN A PATIENT WITH PARKINSONS-DISEASE TREATED WITH PERGOLIDE [J].
JIMENEZJIMENEZ, FJ ;
LOPEZALVAREZ, J ;
SANCHEZCHAPADO, M ;
MONTERO, E ;
MIQUEL, J ;
SIERRA, A ;
GUTIERREZ, F .
CLINICAL NEUROPHARMACOLOGY, 1995, 18 (03) :277-279
[7]  
KAMINSKY P, 1989, PRESSE MED, V18, P777
[8]  
Kunkler RB, 1998, BRIT J UROL, V82, P147
[9]   PLEUROPULMONARY DISEASE DURING BROMOCRIPTINE TREATMENT OF PARKINSON DISEASE [J].
MCELVANEY, NG ;
WILCOX, PG ;
CHURG, A ;
FLEETHAM, JA .
ARCHIVES OF INTERNAL MEDICINE, 1988, 148 (10) :2231-2236
[10]  
Melmed S, 1989, Arch Intern Med, V149, P258, DOI 10.1001/archinte.149.2.258